Real‐life experience with a generic formulation of lumacaftor‐ivacaftor in patients with cystic fibrosis homozygous for the Phe508del CFTR mutation

Abstract

AbstractIntroductionCystic fibrosis (CF) is the most frequent recessive autosomal disorder in the Caucasian population. It is caused by mutations that result in a deficient or dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR) protein activity. Among CFTR modulators, potentiator compounds increase channel opening, whereas corrector compounds increase CFTR quantity in the cell surface.ObjectiveTo report real‐life effects of a generic formulation of lumacaftor‐ivacaftor use in patients with CF homozygous for the Phe508del CFTR mutation.Patients and MethodsClinical variables (body mass index [BMI], pulmonary exacerbations, sweat test, and pulmonary function) were analyzed in 30 CF patients homozygous for the Phe508del CFTR mutation, treated with lumacaftor‐ivacaftor for 12 months, at the Respiratory Center of Hospital de Niños Ricardo Gutiérrez. These clinical variables were compared with those before the use of modulators.ResultsA total of 30 patients with CF homozygous for the Phe508del CFTR mutation receiving lumacaftor‐ivacaftor therapy were included in this study. The median (interquartile range [IQR]) age at the start of treatment was 10.79 (7.08–14.05) years. Nineteen patients were male. Before treatment, median (IQR) sweat chloride concentration was 80 (72–92) mEq/L, and it had decreased to 74 (68–78) mEq/L (p = .05) 12 months after treatment. Median (IQR) BMI z‐score improved from −0.33 (−0.86 to 0.21) to −0.13 (−0.66 to 0.54) (p = .003). A spirometry was performed in 28 of 30 patients. Median (IQR) ppFEV1 was 83.5 (71–91) before treatment and 86.5 (67–103) after treatment (p = .38), 73.3% of patients referred decreased sputum production and 40% reported improvement in their dyspnea at 12 months. Severe pulmonary exacerbations significantly decreased from 60% in the year before treatment, to 30% at 12 months after treatment (p = .037); 13 patients showed an improvement in their exacerbation rates, 2 showed an increased rate, and 15 showed no change.ConclusionsThe use of a generic formulation of lumacaftor‐ivacaftor in patients homozygous for the Phe508del CFTR mutation was associated with improvement in nutritional status and respiratory symptoms, and a significant reduction in severe pulmonary exacerbations.